Mirapexin (Pramipexole Dihydrochloride Monohydrate)

Pramipexole selectively stimulates dopamine D2 and D3 receptors in the brain, especially within basal ganglia circuits. This agonist activity compensates for reduced dopaminergic signaling, helping to improve motor control in Parkinson's disease and to lessen sensory urges in Restless Legs Syndrome.

The dosage of Mirapexin is individualized. A qualified prescriber determines the starting dose, titration schedule, and maintenance dose based on the patient’s clinical condition, response, and tolerability, following local prescribing guidelines.

Safety data for pramipexole during pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category, and it should be used only if the potential benefit justifies any potential risk to the fetus or infant.

To place an order, submit an enquiry on the Mirapexin product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirapexin (pramipexole) is a non‑levodopa dopamine agonist, offering a longer half‑life and once‑daily dosing options compared with immediate‑release levodopa. It may be used as monotherapy in early disease or as an adjunct in later stages, whereas levodopa remains the most potent symptomatic agent but can be associated with motor fluctuations over time.

Mirapexin tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect them from moisture, excessive heat and direct sunlight to maintain product stability throughout its shelf life.

Mirapexin is supplied as oral tablets. Patients should swallow the tablet whole with water, with or without food, as directed by the prescriber. The dose is usually titrated gradually to the therapeutic level that provides symptom control while minimizing side effects.

Serious adverse events include hallucinations, impulse‑control disorders such as compulsive gambling or shopping, sudden onset of sleep (unexpected sleep attacks), and severe depression or suicidal thoughts. Any of these symptoms require immediate medical evaluation and possible discontinuation of therapy.

Mirapexin is contraindicated in patients with known hypersensitivity to pramipexole or any excipients. It should be used with caution in individuals with severe renal impairment, uncontrolled psychiatric illness, or those concurrently taking monoamine oxidase‑B inhibitors. A prescriber must assess each patient’s medical history before initiating therapy.